NO176759C - Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater

Info

Publication number
NO176759C
NO176759C NO901684A NO901684A NO176759C NO 176759 C NO176759 C NO 176759C NO 901684 A NO901684 A NO 901684A NO 901684 A NO901684 A NO 901684A NO 176759 C NO176759 C NO 176759C
Authority
NO
Norway
Prior art keywords
substituted
therapeutically active
analogous process
oxindole derivatives
preparing therapeutically
Prior art date
Application number
NO901684A
Other languages
English (en)
Norwegian (no)
Other versions
NO901684L (no
NO901684D0 (no
NO176759B (no
Inventor
Frederick Jacob Ehrgott
Carl Joseph Goddard
Gary Richard Schulte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO901684D0 publication Critical patent/NO901684D0/no
Publication of NO901684L publication Critical patent/NO901684L/no
Priority to NO934267A priority Critical patent/NO934267D0/no
Priority to NO934268A priority patent/NO177305C/no
Publication of NO176759B publication Critical patent/NO176759B/no
Publication of NO176759C publication Critical patent/NO176759C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO901684A 1989-04-18 1990-04-17 Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater NO176759C (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO934267A NO934267D0 (no) 1989-04-18 1993-11-25 Nye tiofenderivater
NO934268A NO177305C (no) 1989-04-18 1993-11-25 Fremgangsmåte for fremstilling av 3-substituerte-2-oksindol-derivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34011389A 1989-04-18 1989-04-18

Publications (4)

Publication Number Publication Date
NO901684D0 NO901684D0 (no) 1990-04-17
NO901684L NO901684L (no) 1990-10-19
NO176759B NO176759B (no) 1995-02-13
NO176759C true NO176759C (no) 1995-05-24

Family

ID=23331948

Family Applications (1)

Application Number Title Priority Date Filing Date
NO901684A NO176759C (no) 1989-04-18 1990-04-17 Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater

Country Status (33)

Country Link
US (4) US5047554A (sv)
EP (1) EP0393936B1 (sv)
JP (2) JP2506478B2 (sv)
KR (1) KR920006394B1 (sv)
CN (1) CN1022832C (sv)
AP (1) AP142A (sv)
AT (1) ATE118767T1 (sv)
AU (1) AU633767B2 (sv)
BG (1) BG60646B1 (sv)
CA (1) CA2014467C (sv)
CZ (1) CZ284340B6 (sv)
DD (1) DD293822A5 (sv)
DE (1) DE69017066T2 (sv)
DK (1) DK0393936T3 (sv)
EG (1) EG19122A (sv)
ES (1) ES2068334T3 (sv)
FI (1) FI106378B (sv)
GR (1) GR3015811T3 (sv)
HU (2) HUT58314A (sv)
IE (1) IE65091B1 (sv)
IL (3) IL94047A (sv)
IS (1) IS1636B (sv)
MA (1) MA21808A1 (sv)
MX (1) MX20359A (sv)
NO (1) NO176759C (sv)
NZ (1) NZ233320A (sv)
OA (1) OA09205A (sv)
PL (2) PL163951B1 (sv)
PT (1) PT93785B (sv)
RO (1) RO106402B1 (sv)
RU (2) RU2039042C1 (sv)
YU (1) YU47588B (sv)
ZA (1) ZA902871B (sv)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68923673T2 (de) * 1988-10-18 1996-01-18 Pfizer Prodrogen von antiinflammatorischen 3-Acyl-2-oxindol-1-carboxamiden.
SK278175B6 (en) * 1988-10-18 1996-03-06 Pfizer 3-acyl-2-oxindole-1-carboxamides and method of their preparation
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
TW438798B (en) * 1992-10-07 2001-06-07 Pfizer 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
KR950704727A (ko) * 1992-11-23 1995-11-20 알렌 제이, 스피겔 4-클로로-2-티오펜카복실산의 위치선택적 제조 방법(regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid)
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
ES2097025T3 (es) * 1993-02-09 1997-03-16 Pfizer Oxindol 1-(n-(alcoxicarbonil))carboxamidas y 1-(n-carboxamido)carboxamidas como agentes antiinflamatorios.
ES2076106B1 (es) * 1993-08-26 1996-06-16 Pfizer Composiciones farmaceuticas a base de 2-oxindol-1-carboxamidas 3-sustituidas
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
CN1051452C (zh) * 1994-07-26 2000-04-19 中国医学科学院血液学研究所 3-取代芳基氧化吲哚类化合物的应用
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
AU6226598A (en) * 1997-04-04 1998-10-30 Pfizer Inc. Processes and intermediates for preparing 2-fluorothiophene derivatives
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
UA73976C2 (uk) * 2000-02-15 2005-10-17 Суджен, Інк. Заміщені піролом 2-індолінони, фармацевтична композиція, спосіб модуляції каталітичної активності протеїнкінази та спосіб лікування або профілактики захворювання, пов'язаного з протеїнкіназою
WO2002060373A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002070478A1 (en) * 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
JP2005508953A (ja) 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
BR0309412A (pt) 2002-04-22 2005-02-01 Pfizer Prod Inc Indol-2-onas como inibidores seletivos da ciclooxigenase-2
DK1928454T3 (da) 2005-05-10 2014-11-03 Intermune Inc Pyridonderivater til modulering af stress-aktiveret proteinkinasesystem
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8933248B2 (en) 2012-06-21 2015-01-13 Council Of Scientific & Industrial Research 3-substituted-3-hydroxy oxindole derivatives and process for preparation thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
BR122021017872B1 (pt) 2014-06-06 2021-11-23 Basf Se Uso dos compostos, composição agroquímica e método para o combate dos fungos fitopatogênicos
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
BR112018009539B1 (pt) 2015-11-13 2022-05-24 Basf Se Uso de compostos da fórmula i, compostos, mistura, composição agroquímica, uso dos compostos e método para combater fungos nocivos fitopatogênicos
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
BR112018008449B1 (pt) 2015-11-19 2021-07-06 Basf Se Compostos de fórmula i, mistura, composição agroquímica e método para combater fungos nocivos fitopatogênicos
AU2017250397A1 (en) 2016-04-11 2018-10-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN108299354A (zh) * 2017-01-12 2018-07-20 中国科学院宁波材料技术与工程研究所 一种2,5-呋喃二甲酸或其酯化物的制备方法
CN115403566B (zh) * 2022-09-21 2024-01-30 山东大学 3-取代吲哚-2-酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1255658A (en) * 1917-11-12 1918-02-05 Adamson Stephens Mfg Co Carrier for belt conveyers.
BE756447A (fr) * 1969-10-15 1971-03-22 Pfizer Oxindolecarboxamides
US3900563A (en) * 1973-06-18 1975-08-19 American Cyanamid Co Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines
US4721712A (en) * 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
IN162090B (sv) * 1984-03-19 1988-03-26 Pfizer
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
IN161509B (sv) * 1984-05-04 1987-12-19 Pfizer
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US4695571A (en) * 1984-08-24 1987-09-22 Pfizer Inc. Tricyclic oxindole antiinflammatory agents
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
FI80270C (sv) * 1984-09-19 1990-05-10 Pfizer Förfarande för framställning av analgetiska och anti-inflammatoriska 1 ,3-diacyl-2-oxoindol-föreningar och mellanprodukter
US4808601A (en) * 1984-09-19 1989-02-28 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4752609A (en) * 1985-06-20 1988-06-21 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
WO1988003658A1 (en) * 1986-11-14 1988-05-19 Kalervo Alfred August Hermas Lens for receiving and/or transmitting infrared radiation
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives

Also Published As

Publication number Publication date
KR920006394B1 (ko) 1992-08-06
BG60646B1 (bg) 1995-11-30
DE69017066D1 (de) 1995-03-30
DK0393936T3 (da) 1995-06-26
NO901684L (no) 1990-10-19
HU902462D0 (en) 1990-08-28
IE65091B1 (en) 1995-10-04
US5919809A (en) 1999-07-06
IL110173A0 (en) 1994-10-07
MX20359A (es) 1994-02-28
US5290802A (en) 1994-03-01
AP142A (en) 1991-09-26
RO106402B1 (ro) 1993-04-30
OA09205A (en) 1992-06-30
KR900016189A (ko) 1990-11-12
ZA902871B (en) 1991-11-27
US5047554A (en) 1991-09-10
AP9000175A0 (en) 1990-04-30
RU2039042C1 (ru) 1995-07-09
EG19122A (en) 1994-07-30
YU47588B (sh) 1995-10-24
YU75590A (sh) 1992-07-20
NO901684D0 (no) 1990-04-17
IS1636B (is) 1996-09-20
ES2068334T3 (es) 1995-04-16
PL287812A1 (en) 1991-07-15
PL284817A1 (en) 1991-03-25
HUT58314A (en) 1992-02-28
ATE118767T1 (de) 1995-03-15
AU633767B2 (en) 1993-02-04
CA2014467A1 (en) 1990-10-18
NZ233320A (en) 1991-09-25
IL110173A (en) 1997-06-10
CZ184890A3 (cs) 1998-07-15
NO176759B (no) 1995-02-13
AU621477B2 (en) 1992-03-12
PL163941B1 (pl) 1994-05-31
CA2014467C (en) 2000-02-08
BG91773A (bg) 1993-12-24
AU1051092A (en) 1992-04-09
EP0393936B1 (en) 1995-02-22
CN1046525A (zh) 1990-10-31
PL163951B1 (pl) 1994-05-31
PT93785A (pt) 1990-11-20
PT93785B (pt) 1996-09-30
US6174883B1 (en) 2001-01-16
DD293822A5 (de) 1991-09-12
MA21808A1 (fr) 1990-12-31
CZ284340B6 (cs) 1998-10-14
FI106378B (sv) 2001-01-31
IS3570A7 (is) 1990-10-19
IL94047A (en) 1995-10-31
IE901360L (en) 1990-10-18
RU2073671C1 (ru) 1997-02-20
JPH02292258A (ja) 1990-12-03
JP2581525B2 (ja) 1997-02-12
GR3015811T3 (en) 1995-07-31
FI901915A0 (fi) 1990-04-17
JPH07118261A (ja) 1995-05-09
CN1022832C (zh) 1993-11-24
EP0393936A1 (en) 1990-10-24
HU211150A9 (en) 1995-10-30
DE69017066T2 (de) 1995-06-14
JP2506478B2 (ja) 1996-06-12
AU5362690A (en) 1990-11-22
IL94047A0 (en) 1991-01-31

Similar Documents

Publication Publication Date Title
NO176759C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
NO176758C (no) Analogifremgangsmåte for fremstilling av terapeutiske anvendbare tetrazolyl-bifenylylmetyl-pyrimidiner
FI96861C (sv) Förfarande för framställning av terapeutiskt aktiva substituerade indolylpyrrolderivat
NO174385C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive spiro-substituerte glutamid-derivater
NO180586C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte imidazoler
NO174547C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive didehydro-vitamin-D3-derivater
NO175978C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive bis-aza-bicykliske forbindelser
NO180749C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzimidazolsubstituerte derivater
NO174467C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater
NO174959C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive N-aminobutyl-N-fenyl-arylamidderivater
NO175429C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive 16-dehydro-vitamin-D3-derivater
NO178967C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazin-derivater
NO173334C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive alkylaminoalkylenderivater 2H-1-benzopyraner
NO173784C (no) Anaslogifremgangsmaate for fremstilling av terapeutisk aktive tieno-tri-azolo-diazepinderivater
NO176142C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminoalkoksyfenylderivater
NO176477C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-alkoksymetylsubstituerte kromanderivater
NO176100C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive oksodihydropyridyl- og oksodihydropyridazinylkromanderivater
NO174391C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater
NO175781C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive tetracykliske forbindelser
NO175976C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
NO174200C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser
NO174422C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
FI903077A0 (sv) Förfarande för framställning av terapeutiskt aktiva R(-)-3-kinuklidinolderivat

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees